An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients-Reference-Cited by-同舟云学术

An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients

Published:2007-10 Issue:9-10 Volume:17 Page:693-697
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

O’Hagen Jessica M.,Glanzman Allan M.,McDermott Michael P.,Ryan Patricia A.,Flickinger Jean,Quigley Janet,Riley Susan,Sanborn Erica,Irvine Carrie,Martens William B.,Annis Christine,Tawil Rabi,Oskoui Maryam,Darras Basil T.,Finkel Richard S.,De Vivo Darryl C.

Publisher

Elsevier BV

Subject

Genetics(clinical),Clinical Neurology,Neurology,Pediatrics, Perinatology, and Child Health

Reference15 articles.

1. Spinal muscular atrophies;Crawford,2003

2. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies;Melki;Science,1994

3. Quantitative analyses of SMN1 and SMN2 based on real-time light Cycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy;Feldkotter;Am J Hum Genet,2002

4. Therapeutics development for spinal muscular atrophy;Sumner;NeuroRx,2006

5. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells;Grzeschik;Ann Neurol,2005

Cited by 259 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy;Cellular and Molecular Life Sciences;2024-09-10

2. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis;Neurology and Therapy;2024-09-02

3. Nusinersen Improves Motor Function in Type 2 and 3 Spinal Muscular Atrophy Patients across Time;Biomedicines;2024-08-06

4. Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA;Neuromuscular Disorders;2024-08

5. Exploring functional strength changes during nusinersen treatment in symptomatic children with SMA types 2 and 3.;Neuromuscular Disorders;2024-08